Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03638427 · ClinicalTrials.gov registry record
Screening for Cervical Intraepithelial Neoplasia Using Self-collected Menstrual Blood
A clinical trial, sponsored by Stanford University.
- Completed
- Registry status
- 159
- Enrollment target
NCT03638427: Completed study, sponsored by Stanford University.
NCT03638427 is a clinical trial that has completed, run by Stanford University. The registered enrollment target is 159 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03638427 has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 159 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the feasibility and efficacy of assessing HR-HPV DNA and HPV E6/E7 mRNA via self-collected menstrual blood in a smart menstrual pad. In other words, can the investigators detect the high risk strains of the human papilloma virus (HPV) that are associated with cervical cancer in self-collected menstrual blood, as an alternative to collecting vaginal swabs.
Interventions
- DIAGNOSTIC_TEST Menstrual Blood Analysis (Menstrual Blood Analysis)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2019-01-01 |
| Est. Completion | 2022-11-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03638427
The ClinicalTrials.gov registry entry for NCT03638427 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 159 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Menstrual Blood Analysis (Menstrual Blood Analysis) is the first listed.
NCT03638427 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03638427 about?
NCT03638427 is a clinical study titled "Screening for Cervical Intraepithelial Neoplasia Using Self-collected Menstrual Blood". The purpose of this study is to investigate the feasibility and efficacy of assessing HR-HPV DNA and HPV E6/E7 mRNA via self-collected menstrual blood in a smart menstrual pad. In other words, can the investigators detect the high risk strains of the human papilloma virus (HPV) that are associated w...
What is the current status of trial NCT03638427?
This trial is currently completed. The enrollment target is 159 participants. The study started on 2019-01-01. Estimated completion is 2022-11-30.
What interventions are being tested in trial NCT03638427?
The interventions under investigation include: Menstrual Blood Analysis (Menstrual Blood Analysis) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03638427?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.